In a new study by researchers at Brigham and Women’s Hospital and Harvard Medical School, A new method has been developed for the treatment of postoperative gliomaUse Stem cells from healthy donorsDesigned to attack cancer cells Specific GBM. This strategy has proven to be very effective in preclinical GBM models, where it is 100%. The mice survived more than 90 days after treatment.
This is the first study to identify target receptors on cancer cells before initiating therapy and to use modified, biodegradable, gel-coated, gel-coated stem cell therapy after GBM surgery. In the future, we will use this strategy to quickly identify target receptors after receiving a diagnosis of GBM, and then administer modified stem cell therapy as a gel capsule from a prepared reservoir, said Dr. Khalid Shah of the Department. Brigham of Neurosurgery, Lecturer at Harvard Medical School and Cell Institute. Harvard Stem University (HSCI).
Many cell therapies are used to treat cancer It comes from the patient’s stem cells or immune cells. However, in the case of GBM, due to the rapid progression of the disease, most patients undergo surgery in the first week after diagnosis, leaving little time for the development of treatments in their own cell types. Instead, scientists have developed a new approach to exploitation allogeneic stem cells, ie cells from healthy people, so that the drug is readily available and can be administered immediately after surgery. Dr. Shah’s team evaluated the effectiveness of several capsules that carry stem cells to the brain and found that capsule with biodegradable hydrogel It transfers it efficiently without rinsing it with cerebrospinal fluid.
Scientists have first identified special receptors called “death receptors” Found in circulating tumor cells (CTC), ie cancer cells in the blood, using a common genetic marker in cancer cells. Once selected, downloaded bifunctional stem cells (MSCBif) is extracted from the bone marrow of healthy people and is modified to release a protein that binds to a death receptor and initiates cell death. Dr. Shah’s team evaluated the efficacy of this treatment in animal models of primary and recurrent GBM tumor postoperatively.
All mice received stem cell gel therapy after surgery They lived 90 days after treatment, compared to mice that had only surgerywhich had an average survival of 55 days. In addition, the safety of this treatment was assessed by conducting several studies using different doses of MSC treatment in mice. They found no signs of toxicity in mice with or without tumors.
The results of the study pave the way for Phase 1 clinical trials in GBM patients undergoing brain surgery over the next two years. Dr. Shah’s team noted that this The therapeutic strategy will be applied to a wider range of solid tumors and that further research into its use is warranted.
In addition to being an important indicator of the effectiveness of this treatment, these results suggest that we can use stem cells from healthy people to treat cancer patients. This work is the basis for the beginning of the construction of a biobank of stem cells with therapeutic properties, targeting different receptors of cancer cells and immune cells in the tumor microenvironment, which one day we can use to treat a wide range of challenging conditions. . “To treat cancers like GBM,” Dr. Shah concluded.
–
